
The Johnson & Johnson COVID-19 vaccine will continue its rollout in Europe, following a review from the EMA.

Adagio Therapeutics has financed $336 million to support the rapid advancement of their novel ADG20 antibody for the treatment and …

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

The European Commission (EC) has approved a second indication of Sanofi’s Sarclisa drug for the treatment of adult patients with …

A number of new COVID-19 developments have dominated the news again this week: J&J’s vaccine for the virus has been …

Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.

The EMA have begun a review of GSK and Vir Biotechnology’s investigational COVID-19 antibody (VIR-7831) for patients at high risk …

The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).

Roche’s Evrysdi therapy for the treatment of children with type 1 spinal muscular atrophy (SMA) has been shown to increase …

The past week has seen plenty of good and bad COVID-19 vaccine news; the EMA and CDC have launched investigations …

The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the …

AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …

Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …

A number of new COVID-19 developments have emerged in April already: AstraZeneca has halted the trial of its COVID-19 vaccine …